B72:FRA
AtaiBeckley Inc
€3.72
arrow_upward
+3.33%(+0.12) 1D
වෙසක් 19, 08.00.44 ග්රිමවේ+2 · EUR
search
සියලු සංකේත
1D
5D
1M
6M
YTD
1Y
5Y
උපරි
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoB72 සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
€3.72
ඉහළ
€3.72
පහළ
€3.72
වෙ.පො ප්රාග්ධනය
බි1.48
දළ පරිමාව
ද3.02
හඬ පරිමාණය
70.00
සති-52 ඉහළ
€5.30
සති-52 පහළ
€2.70
සේවකයින් ගණන
99
පුවත් සහ කථා
වෙබය හරහා මූලාශ්ර වෙතින්
Simply Wall Street
·
පැය 8කට පෙර
Assessing AtaiBeckley (ATAI) Valuation After First Quarter Loss And Improved Per Share Results
Quiver Quantitative
·
දින 1කට පෙර
$ATAI stock is up 8% today. Here's what we see in our data.
පැතිකඩ
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
AtaiBeckley Inc ගැන
AI අන්තර්ගතයේ වැරදි ඇතුළත් විය හැක. තව දැන ගන්න